MOUD Buprenorphine Subli denied due to quantity / dose limits by Centene?

Mirrors state Medicaid PDLs. Most state Medicaid programs (post-2023 X-waiver removal) allow PCP prescribing without specialist gatekeeping.

MATA Act 2022 / DATA 2000 X-waiver removal — any DEA-registered prescriber may prescribe buprenorphine. ASAM NPG OUD 2020 first-line. SAMHSA TIP 63 supports doses >24 mg for fentanyl-era patients. EPSDT for under-21.

## Why Centene Limits Quantity for Sublingual Buprenorphine — and Why You Can Fight Back

Centene and its subsidiary health plans (Ambetter, WellCare, Magnolia Health, and others) routinely apply quantity limits to sublingual buprenorphine films and tablets used for medication for opioid use disorder (MOUD). The plan's formulary typically caps fills at a fixed number of doses per month, and claims that exceed that ceiling are automatically denied. These limits exist primarily for cost-control reasons, but they frequently conflict with a patient's individualized clinical picture — particularly during induction, dose titration, or periods of heightened craving risk.

Quantity-limit denials are among the most winnable appeals when documentation is thorough.

## Federal Appeal Rights

You have layered federal protections:

• Internal appeal (ACA §2719 / ERISA §503): You must file a first-level internal appeal. For a non-urgent situation you typically have 180 days from the denial notice; plans must respond within 30 days for pre-service and 60 days for post-service claims.
• Expedited internal appeal: If the standard timeline would seriously jeopardize your health or ability to regain maximum function, request an expedited review — plans must respond within 72 hours.
• External independent review (ACA §2719): After exhausting internal appeals (or if the plan misses its deadline), you may request external review. The external reviewer is independent of the plan. Federal rules protect a roughly four-month window (generally 4 months from the denial) to initiate this step.
• State insurance commissioner: Many states have additional quantity-limit protections for MOUD; filing a parallel complaint often accelerates insurer response.

## The Appeal Process: Step by Step

1. Obtain the denial letter — confirm the exact quantity limit cited and the plan's stated rationale. 2. Pull the plan's published coverage/formulary policy — Centene is required to post its medical necessity and quantity-limit criteria publicly. Match every criterion listed to your documentation. 3. File the internal appeal in writing within the plan's deadline, requesting expedited review if clinically warranted. 4. If denied internally, request external review promptly — do not wait.

## Documentation to Gather

• Diagnosis confirmation: Chart notes, DSM-5 diagnostic documentation, and urine drug screen history establishing opioid use disorder.
• Current treatment history: Start date of buprenorphine therapy, doses prescribed at each stage, and clinical rationale for the current prescribed quantity (e.g., split dosing, induction protocol, titration).
• Clinical severity: Documentation of prior relapse history, overdose events, co-occurring conditions, and functional status that support the medical necessity of the quantity requested.
• Prescriber medical-necessity letter: Your prescribing clinician should explain in writing why the quantity requested is individually appropriate, referencing the FDA-approved prescribing information and applicable SAMHSA or ASAM clinical guidelines — without specifying numbers, but citing the standard of care framework.
• FDA label reference: The prescriber's letter should note that the requested quantity is consistent with FDA-approved prescribing information for this indication.

## Criteria-Mapping Structure

Create a two-column table in your appeal:

| Plan Requirement (from denial/policy) | Supporting Chart Documentation | |---|---| | Diagnosis of opioid use disorder | [Date of diagnosis, clinician, DSM criteria met] | | Prescribed by a waivered/certified provider | [Provider DEA-X or applicable credential] | | Quantity within FDA-labeled range | [Prescriber attestation citing label] | | Medical necessity for quantity exceeding limit | [Clinical rationale letter with chart citations] |

Answer every requirement the plan lists. Unanswered criteria are the most common reason appeals fail at the external-review stage.